Tolerance and effectiveness of anti-tumor necrosis factor α therapies in elderly patients with rheumatoid arthritis: A population-based cohort study

Arthritis Care and Research

Volumn 57, Issue 4, 2007, Pages 679-685

  Genevay, Stéphane ^a   Finckh, Axel ^a   Ciurea, Adrian ^b   Chamot, Anne Marie ^c   Kyburz, Diego ^b   Gabay, Cem ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c University Hospital of Geneva ^*

Author keywords

Anti tumor necrosis factor; Rheumatoid arthritis: Elderly

Indexed keywords

ADALIMUMAB; ETANERCEPT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLERGIC REACTION; ARTICLE; CANCER; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG TOLERANCE; EPIGASTRIC PAIN; FEMALE; HALLUCINATION; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH PROGRAM; HUMAN; INFECTION; LIVER CIRRHOSIS; LONGITUDINAL STUDY; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT ASSESSMENT; RHEUMATOID ARTHRITIS; TOTAL QUALITY MANAGEMENT;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DATABASES, FACTUAL; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS INDICATORS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34248561928     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.22688     Document Type: Article

References (21)

1. Sewell KL. Rheumatoid arthritis in older adults. Clin Geriatr Med 1998;14:475-94.
2. Criscione LG, St Clair EW. Tumor necrosis factor-α antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002;14:204-11.
3. Bathon JM, Fleischmann RM, van der Heijde D, Tesser JR, Peloso PM, Chon Y, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006;33:234-43.
4. Fleischmann RM, Baumgartner SW, Tindall EA, Weaver AL, Moreland LW, Schiff MH, et al. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol 2003;30:691-6.
5. Harrison MJ, Kim CA, Silverberg M, Paget SA. Does age bias the aggressive treatment of elderly patients with rheumatoid arthritis? J Rheumatol 2005;32:1243-8.
6. Percy LA, Fang MA. Geropharmacology for the rheumatologist. Rheum Dis Clin North Am 2000;26:433-54.
7. Uitz E, Fransen J, Langenegger T, Stucki G, for the members of the Swiss Clinical Quality Management in Rheumatoid Arthritis. Clinical quality management in rheumatoid arthritis: putting theory into practice. Rheumatology (Oxford) 2000;39:542-9.
8. Finckh A, Simard JF, Gabay C, Guerne PA, for the SCQM physicians. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006;65:746-52.
9. Genta MS, Kardes H, Gabay C. Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti-TNF-α in the community. Joint Bone Spine 2006;73:51-6.
10. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis [review]. Baillieres Clin Rheumatol 1995;9:619-32.
11. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005;23 Suppl 39:S93-9.
12. Mason JH, Anderson JJ, Meenan RF, Haralson KM, Lewis-Stevens D, Kaine JL. The Rapid Assessment of Disease Activity in Rheumatology (RADAR) questionnaire: validity and sensitivity to change of a patient self-report measure of joint count and clinical status. Arthritis Rheum 1992;35:156-62.
13. Stucki G, Liang MH, Stucki S, Bruhlmann P, Michel BA. A self-administered Rheumatoid Arthritis Disease Activity Index (RADAI) for epidemiologic research: psychometric properties and correlation with parameters of disease activity. Arthritis Rheum 1995;38:795-8.
14. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703.
15. Yung RL. Changes in immune function with age. Rheum Dis Clin North Am 2000;26:455-73.
16. Terkeltaub R, Esdaile J, Decary F, Tannenbaum H. A clinical study of older age rheumatoid arthritis with comparison to a younger onset group. J Rheumatol 1983;10:418-24.
17. Nesher G, Moore TL. Rheumatoid arthritis in the aged: incidence and optimal management [review]. Drugs Aging 1993;3:487-501.
18. Mavragani CP, Moutsopoulos HM. Rheumatoid arthritis in the elderly. Exp Gerontol 1999;34:463-71.
19. Olivieri I, Palazzi C, Peruz G, Padula A. Management issues with elderly-onset rheumatoid arthritis: an update. Drugs Aging 2005;22:809-22.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006;54:600-6.